Biogen Snags FDA Approval for Second Hemophilia Drug

The U.S. FDA said on Friday it approved Biogen Idec's long-lasting hemophilia A drug, Eloctate, adding another product to the company's emergent portfolio of non-malignant blood disorder drugs.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news